Abstract

Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types of therapies, including immunotherapies. Epigenetic reprogramming is a key molecular hallmark in tumors across cancer types, including glioma. Mounting evidence highlights a pivotal role of epigenetic regulation in shaping tumor biology and therapeutic responses through mechanisms involving both glioma cells and immune cells, as well as their symbiotic interactions in the tumor microenvironment (TME). In this review, we discuss the molecular mechanisms of epigenetic regulation that impacts glioma cell biology and tumor immunity in both a cell-autonomous and non-cell-autonomous manner. Moreover, we provide an overview of potential therapeutic approaches that can disrupt epigenetic-regulated tumor-immune symbiosis in the glioma TME.

MeSH

Molecular Biology, Immunotherapy, Cells, Therapeutics, Clinical Medicine, Neoplasms, Glioma, Symbiosis, Cell Biology

Cited by

• Targeting legumain-mediated cell-cell interaction sensitizes glioblastoma to immunotherapy in preclinical models. J Clin Invest, 2025
• Long Non-Coding RNA : A Comprehensive Overview on Its Biological Functions and Clinical Significances in Human Cancers. Molecules, 2024
• Protease regulation of tumor-immune cell symbiosis. Trends Cancer, 2025
• Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma. Commun Biol, 2024
• Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression. JCI Insight, 2025
• Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J Clin Invest, 2024
• Epigenetic regulation of tumor immunity. J Clin Invest, 2024